Journal article · 2014 · Open access
Patient preferences in advanced or recurrent ovarian cancer
Cancer, 120(23), 3651–3659 · Published 4 August 2014 · DOI 10.1002/cncr.28940
In brief
“Patient preferences in advanced or recurrent ovarian cancer” is a 2014 journal article by Laura Jean Havrilesky and 11 co-authors, published in Cancer. OpenAlex counts 85 citations as of 22 November 2026, which puts it in the top 8% of works published in 2014 by citations. It is open access: the full text is free to read at Cancer.
- Citations
- 85
- Most cited in
- 2019 (13)
- Field-weighted impact
- 2.51
- References
- 23
- Authors
- 12
Abstract
BACKGROUND: The objective of this study was to elucidate relative preferences of women with ovarian cancer for symptoms, treatment-related side effects, and progression-free survival (PFS) relevant to choosing a treatment regimen. METHODS: Women with advanced or recurrent ovarian cancer participated in a survey that included 3 methods to measure patient preferences (ratings, rankings, and a discrete-choice experiment) for 7 attributes: mode of administration, visit frequency, peripheral neuropathy, nausea and vomiting, fatigue, abdominal discomfort, and PFS. Participants were asked to choose between 2 unlabeled treatment scenarios that were characterized using the 7 attributes. Each participant completed 12 choice questions in which attribute levels were assigned according to an experimental design and a fixed-choice question representing 2 chemotherapy regimens for ovarian cancer. RESULTS: In total, 95 women completed the survey. Participants' ratings and rankings revealed greater concern and importance for PFS than for any other attribute (P < .0001 for all). The discrete-choice experiment revealed that the relative odds that a participant would choose a scenario with 18 months, 21 months, and 24 months of PFS versus 15 months of PFS were 1.5 (P = .01), 3.4 (P < .001), and 7.5 (P < .001), respectively. However, participants' choices indicated that they were willing to accept a shorter PFS to avoid severe side effects: 6.7 months to reduce nausea and vomiting from severe to mild, 5.0 months to reduce neuropathy from severe to mild, and 3.7 months to reduce abdominal symptoms from severe to moderate. CONCLUSIONS: PFS is the predominant driver of patient preferences for chemotherapy regimens. However, women in the current study were willing to trade significant PFS time for reductions in treatment-related toxicity.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Havrilesky, L. J., Secord, A. A., Ehrisman, J. A., Berchuck, A., Valea, F. A., Lee, P. S., Gaillard, S. L., Samsa, G., Cella, D. F., Weinfurt, K. P., Abernethy, A. P., & Reed, S. D. (2014). Patient preferences in advanced or recurrent ovarian cancer. Cancer, 120(23), 3651–3659. https://doi.org/10.1002/cncr.28940
MLA 9
Havrilesky, Laura Jean, et al. “Patient preferences in advanced or recurrent ovarian cancer.” Cancer, vol. 120, no. 23, 2014, pp. 3651–3659. https://doi.org/10.1002/cncr.28940.
Chicago
Havrilesky, Laura Jean, Angeles Alvarez Secord, Jessie A. Ehrisman, Andrew Berchuck, Fidel A. Valea, Paula S. Lee, Stephanie L. Gaillard, et al. 2014. “Patient preferences in advanced or recurrent ovarian cancer.” Cancer 120 (23): 3651–3659. https://doi.org/10.1002/cncr.28940.
Harvard
Havrilesky, L. J. et al. (2014) ‘Patient preferences in advanced or recurrent ovarian cancer’, Cancer, 120(23), pp. 3651–3659. doi:10.1002/cncr.28940.
IEEE
L. J. Havrilesky et al., “Patient preferences in advanced or recurrent ovarian cancer,” Cancer, vol. 120, no. 23, pp. 3651–3659, 2014, doi: 10.1002/cncr.28940.
BibTeX
@article{havrilesky2014patient,
title = {{Patient preferences in advanced or recurrent ovarian cancer}},
author = {Havrilesky, Laura Jean and Secord, Angeles Alvarez and Ehrisman, Jessie A. and Berchuck, Andrew and Valea, Fidel A. and Lee, Paula S. and Gaillard, Stephanie L. and Samsa, Greg and Cella, David F and Weinfurt, Kevin P. and Abernethy, Amy P. and Reed, Shelby D.},
journal = {Cancer},
year = {2014},
volume = {120},
number = {23},
pages = {3651--3659},
doi = {10.1002/cncr.28940},
url = {https://doi.org/10.1002/cncr.28940}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2017 | 10 | |
| 2018 | 10 | |
| 2019 | 13 | |
| 2020 | 9 | |
| 2021 | 11 | |
| 2022 | 7 | |
| 2023 | 8 | |
| 2024 | 2 | |
| 2025 | 5 | |
| 2026 | 3 |
Its field-weighted citation impact is 2.51: it has been cited 2.51 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- ovarian cancer
- patient preferences
- treatment side effects
- progression-free survival
- chemotherapy regimens
- peripheral neuropathy
- nausea and vomiting
- fatigue
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Havrilesky, L. J., Secord, A. A., Ehrisman, J. A., Berchuck, A., Valea, F. A., Lee, P. S., Gaillard, S. L., Samsa, G., Cella, D. F., Weinfurt, K. P., Abernethy, A. P., & Reed, S. D. (2014). Patient preferences in advanced or recurrent ovarian cancer. Cancer, 120(23), 3651–3659. https://doi.org/10.1002/cncr.28940
How many times has this paper been cited?
85 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Cancer: sign in and open the PDF from this page.
Who wrote this paper?
Laura Jean Havrilesky, Angeles Alvarez Secord, Jessie A. Ehrisman, Andrew Berchuck, Fidel A. Valea, Paula S. Lee, Stephanie L. Gaillard, Greg Samsa, David F Cella, Kevin P. Weinfurt, Amy P. Abernethy, Shelby D. Reed.
What is the DOI of this paper?
10.1002/cncr.28940, permanently at https://doi.org/10.1002/cncr.28940. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.